Heyholder
‹ Activism Filings

Orum Therapeutics, Inc. Periodic Report


AI summary · Not investment advice

Orum Therapeutics sold about KRW 24.9 million in Q3 and lost KRW 16.1 billion from its main business, versus a loss of KRW 13.9 billion a year earlier.

Operating profit · 3 months

KRW -16.1 billion

Key facts

Revenue (3 months)
KRW 24.9 million
Net income (3 months)
KRW -18.4 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 15.9 million
Revenue (year to date)
KRW 49.0 million
Operating profit (prior-year 3 months)
KRW -13.9 billion
Operating profit (year to date)
KRW -49.5 billion
Net income (prior-year 3 months)
KRW -13.6 billion
Net income (year to date)
KRW 29.7 billion

Commentary

AI commentary · Not investment advice

What happened

Oreum Therapeutics filed its quarterly report with consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 24.9 million, up 56.4% from KRW 15.9 million a year earlier. Cumulative sales this year are KRW 48.96 million.

In the company's terms

Operating profit (profit from the core business) for the latest 3 months was a loss of KRW 16.08 billion. A year earlier, the same 3 months showed a loss of KRW 13.94 billion. Cumulative operating profit this year is a loss of KRW 49.51 billion.

What changes for shareholders

Net income (the final profit after taxes and all other items) for the latest 3 months was a loss of KRW 18.44 billion. A year earlier, the same 3 months showed a loss of KRW 13.62 billion. Cumulative net income this year is positive at KRW 29.66 billion.

Comments

No comments yet

Comments from shareholders will appear here.